Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2017 06:45 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
May 02, 2017 16:05 ET | Source: Apricus Biosciences

Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements

SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on...
April 21, 2017 06:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Pricing of $7.0 Million Public Offering

SAN DIEGO, April 21, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the...
March 13, 2017 16:12 ET | Source: Apricus Biosciences

Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results

Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals Strengthens Financial Position Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017 Conference Call / Webcast Today,...
March 09, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call

SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
March 08, 2017 16:01 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals

Apricus Expects to Receive Approximately $12.7 Million from Ferring Apricus to Focus on Vitaros U.S. NDA Re-Submission and Pipeline Assets Post-ClosingSAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) --...
February 09, 2017 06:00 ET | Source: Apricus Biosciences

Apricus Biosciences Receives Positive Nasdaq Listing Determination

SAN DIEGO, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on...
February 08, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference

SAN DIEGO, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
January 18, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico

SAN DIEGO, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...
January 03, 2017 07:00 ET | Source: Apricus Biosciences

Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel

SAN DIEGO, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right